Compare Abeona Therapeutics Inc (ABEO) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Citius Pharmaceuticals Inc — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while Citius Pharmaceuticals Inc trades at $0.56 (market cap $15.98M). The key difference: Abeona Therapeutics Inc is far larger — about 23.4× Citius Pharmaceuticals Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | CTXR | |
|---|---|---|
Market Cap | $373.32M | $15.98M |
Sector | Health | Health |
52-Week High | $7.23 | $1.94 |
52-Week Low | $4.17 | $0.53 |
Enterprise Value | $228.22M | $12.19M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
CTXR trades at $0.6075, up 5.73% in the last session, with a neutral technical signal and bearish moving averages. The company reported a net loss of $37.43 million for 2025, with a negative net income margin of -823.34%, while generating $5.6 million in revenue in the first half of 2026 from its LYMPHIR launch. Recent news highlights positive Phase 1 data for LYMPHIR presented at ASCO, though earnings have consistently missed expectations.
The outlook remains speculative, with significant upside potential if LYMPHIR gains commercial traction, but high execution risks and persistent losses pose substantial downside. Analyst consensus is strongly bullish at 83.3% buy ratings, reflecting optimism on the drug pipeline, yet investors face dilution risks from recent financing and the challenge of achieving profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
